ECSP22082943A - CONJUGADOS DE INTERLEUCINA 2 HUMANA SESGADOS AL DÍMERO DEL RECEPTOR DE INTERLEUCINA 2 βγc Y CONJUGADOS CON UN POLÍMERO HIDROSOLUBLE NO PEPTÍDICO - Google Patents

CONJUGADOS DE INTERLEUCINA 2 HUMANA SESGADOS AL DÍMERO DEL RECEPTOR DE INTERLEUCINA 2 βγc Y CONJUGADOS CON UN POLÍMERO HIDROSOLUBLE NO PEPTÍDICO

Info

Publication number
ECSP22082943A
ECSP22082943A ECSENADI202282943A ECDI202282943A ECSP22082943A EC SP22082943 A ECSP22082943 A EC SP22082943A EC SENADI202282943 A ECSENADI202282943 A EC SENADI202282943A EC DI202282943 A ECDI202282943 A EC DI202282943A EC SP22082943 A ECSP22082943 A EC SP22082943A
Authority
EC
Ecuador
Prior art keywords
interleukin
conjugates
βγc
soluble polymer
conjugated
Prior art date
Application number
ECSENADI202282943A
Other languages
English (en)
Inventor
Yam Alice
Abrahams Cristina
stafford Ryan
Solis Willy
Bowman Edward
Yang Junhao
Willingham Aarron
Yin Gang
Lin Songnian
Li Xiaofan
Original Assignee
Merck Sharp Dohme Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp Dohme Llc filed Critical Merck Sharp Dohme Llc
Publication of ECSP22082943A publication Critical patent/ECSP22082943A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Se describen conjugados de interleucina 2 (IL-2) que comprenden al menos una o más sustituciones de aminoácidos que sesgan la unión al dímero del receptor de IL-2 βγc con respecto a la unión del trímero del receptor IL-2 αβγc y un aminoácido no natural en o cerca del extremo N conjugado con un polímero hidrosoluble. Los conjugados de IL-2 son útiles para el tratamiento y la prevención de la proliferación celular y el cáncer en un paciente.
ECSENADI202282943A 2020-04-22 2022-10-24 CONJUGADOS DE INTERLEUCINA 2 HUMANA SESGADOS AL DÍMERO DEL RECEPTOR DE INTERLEUCINA 2 βγc Y CONJUGADOS CON UN POLÍMERO HIDROSOLUBLE NO PEPTÍDICO ECSP22082943A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063013583P 2020-04-22 2020-04-22

Publications (1)

Publication Number Publication Date
ECSP22082943A true ECSP22082943A (es) 2022-11-30

Family

ID=75801675

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202282943A ECSP22082943A (es) 2020-04-22 2022-10-24 CONJUGADOS DE INTERLEUCINA 2 HUMANA SESGADOS AL DÍMERO DEL RECEPTOR DE INTERLEUCINA 2 βγc Y CONJUGADOS CON UN POLÍMERO HIDROSOLUBLE NO PEPTÍDICO

Country Status (20)

Country Link
US (2) US11827684B2 (es)
EP (1) EP4139340A1 (es)
JP (1) JP7415047B2 (es)
KR (1) KR20230004682A (es)
CN (1) CN115916811A (es)
AR (1) AR121891A1 (es)
AU (1) AU2021259426B2 (es)
BR (1) BR112022021482A2 (es)
CA (1) CA3176515A1 (es)
CL (1) CL2022002864A1 (es)
CO (1) CO2022015044A2 (es)
CR (1) CR20220530A (es)
EC (1) ECSP22082943A (es)
GE (1) GEP20257834B (es)
IL (1) IL297329A (es)
JO (1) JOP20220266A1 (es)
MX (1) MX2022013291A (es)
PE (1) PE20231648A1 (es)
PH (1) PH12022552719A1 (es)
WO (1) WO2021216478A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021206449A1 (en) 2020-01-10 2022-07-21 Bright Peak Therapeutics Ag Modified IL-2 polypeptides and uses thereof
US20240255492A1 (en) * 2021-06-08 2024-08-01 Merck Sharp & Dohme Llc Functional cell-based potency assay for measuring biological activity of interleukin 2 (il-2) analogs
KR20240041378A (ko) 2021-07-09 2024-03-29 브라이트 피크 테라퓨틱스 아게 체크포인트 억제제와 il-2의 접합체 및 이의 용도
EP4366781A1 (en) 2021-07-09 2024-05-15 Bright Peak Therapeutics AG Checkpoint inhibitors conjugated to il-2, and uses thereof
WO2023281485A1 (en) 2021-07-09 2023-01-12 Bright Peak Therapeutics Ag Modified il-2 polypeptides for treatment of inflammatory and autoimmune diseases
US20230201364A1 (en) 2021-07-09 2023-06-29 Bright Peak Therapeutics Ag Antibody conjugates and manufacture thereof
WO2023281482A1 (en) 2021-07-09 2023-01-12 Bright Peak Therapeutics Ag Cd20-targeted il-2 and its uses
WO2023161857A1 (en) 2022-02-23 2023-08-31 Bright Peak Therapeutics Ag Bifunctional cytokine compositions
WO2023244517A1 (en) * 2022-06-16 2023-12-21 Merck Sharp & Dohme Llc Interleukin-2 prodrugs
WO2024150175A1 (en) 2023-01-11 2024-07-18 Bright Peak Therapeutics Ag Conditionally activated proteins and methods of use
US20240417436A1 (en) 2023-01-11 2024-12-19 Bright Peak Therapeutics Ag Conditionally activated immunocytokines and methods of use
WO2024215989A1 (en) 2023-04-14 2024-10-17 Sotio Biotech Inc. ENGINEERED IMMUNE CELLS FOR TREATING CANCER IN COMBINATION WITH IL-2/IL-15 RECEPTOR βγ AGONISTS

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1985000817A1 (en) 1983-08-10 1985-02-28 Amgen Microbial expression of interleukin ii
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US4902502A (en) 1989-01-23 1990-02-20 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
US5229109A (en) 1992-04-14 1993-07-20 Board Of Regents, The University Of Texas System Low toxicity interleukin-2 analogues for use in immunotherapy
US5534615A (en) 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US6362254B2 (en) 1998-03-12 2002-03-26 Shearwater Corporation Poly(ethylene glycol) derivatives with proximal reactive groups
US6955807B1 (en) 1998-05-15 2005-10-18 Bayer Pharmaceuticals Corporation IL-2 selective agonists and antagonists
DK2128246T3 (da) 2001-04-19 2014-05-12 Univ California Fremgangsmåder og sammensætninger til fremstilling af ortogonale tRNA-aminoacyl-tRNA-syntetasepar.
CA2508939A1 (en) 2002-12-22 2004-07-15 The Scripps Research Institute Protein arrays
JP2006180701A (ja) 2003-02-10 2006-07-13 Institute Of Physical & Chemical Research チロシルｔＲＮＡ合成酵素の変異体及びその作製方法
EP2793027B1 (en) 2003-06-18 2019-11-13 The Scripps Research Institute Unnatural reactive amino acid genetic code additions
US7569215B2 (en) 2003-07-18 2009-08-04 Massachusetts Institute Of Technology Mutant interleukin-2 (IL-2) polypeptides
WO2005091956A2 (en) * 2004-03-05 2005-10-06 Chiron Corporation In vitro test system for predicting patient tolerability of therapeutic agents
US8431558B2 (en) 2004-11-01 2013-04-30 The Regents Of The University Of California Compositions and methods for modification of biomolecules
PT1812031E (pt) 2004-11-01 2015-10-01 Univ California Composições e métodos para modificação de biomoléculas
AU2005319518B2 (en) 2004-12-22 2010-09-09 Ambrx, Inc. Compositions of aminoacyl-tRNA synthetase and uses thereof
CN103059138B (zh) 2005-05-09 2015-10-28 小野药品工业株式会社 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法
US20080096819A1 (en) 2006-05-02 2008-04-24 Allozyne, Inc. Amino acid substituted molecules
WO2007134181A2 (en) 2006-05-11 2007-11-22 Isis Pharmaceuticals, Inc. 5'-modified bicyclic nucleic acid analogs
AU2007271398B2 (en) 2006-07-06 2013-06-20 Merck Patent Gmbh Compositions and methods for enhancing the efficacy of IL-2 mediated immune responses
CN101104077A (zh) 2006-07-12 2008-01-16 北京紫辰医药生物技术研究所 重组人白介素-2与聚乙二醇的偶合物
JP5615558B2 (ja) 2007-02-28 2014-10-29 セリナ・セラピユーテイツクス・インコーポレーテツド 活性ポリオキサゾリンおよびそれを含む組成物
EP3222634A1 (en) 2007-06-18 2017-09-27 Merck Sharp & Dohme B.V. Antibodies to human programmed death receptor pd-1
US8906356B2 (en) 2007-11-05 2014-12-09 Massachusetts Institute Of Technology Mutant interleukin-2 (IL-2) polypeptides
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
EP2306986B1 (en) 2008-06-26 2018-03-21 Prolynx Llc Prodrugs and drug-macromolecule conjugates having controlled drug release rates
WO2010014258A2 (en) 2008-08-01 2010-02-04 Nektar Therapeutics Al, Corporation Conjugates having a releasable linkage
MX2011007647A (es) 2009-01-21 2011-09-01 Amgen Inc Composiciones y metodos para el tratamiento de enfermedades inflamatorias y autoinmunes.
US8258347B2 (en) 2009-02-19 2012-09-04 University Of Georgia Research Foundation, Inc. Cyclopropenones and the photochemical generation of cyclic alkynes therefrom
US8519122B2 (en) 2010-02-12 2013-08-27 The Regents Of The University Of California Compositions and methods for modification of biomolecules
CN107235828B (zh) 2010-04-27 2024-06-07 西纳福克斯股份有限公司 稠合的环辛炔化合物及其在无金属点击反应中的应用
ES2584381T3 (es) 2010-05-05 2016-09-27 Prolynx Llc Liberación controlada de compuestos activos desde conjugados macromoleculares
US8912322B2 (en) 2010-07-29 2014-12-16 University Of Georgia Research Foundation, Inc. Aza-dibenzocyclooctynes and methods of making and using same
CU23923B1 (es) 2010-11-12 2013-07-31 Ct De Inmunología Molecular Polipéptidos derivados de la il-2 con actividad agonista
HRP20210642T1 (hr) 2010-11-12 2021-05-28 Nektar Therapeutics Konjugati il-2 ostatka i polimera
US20140011235A1 (en) 2010-12-02 2014-01-09 Salk Institute For Biological Studies Release factor 1 (rf1) in escherichia coli
US9428567B2 (en) 2010-12-22 2016-08-30 The Board Of Trustees Of The Leland Stanford Junior University Antagonists of interleukin-2 receptor
LT3075745T (lt) 2011-02-10 2018-11-26 Roche Glycart Ag Mutavę interleukino-2 polipeptidai
WO2012134925A1 (en) 2011-03-25 2012-10-04 Life Technologies Corporation Heterobifunctional esters for use in labeling target molecules
US20130251783A1 (en) 2011-09-14 2013-09-26 Universitat Heidelberg Liposomes containing permeation enhancers for oral drug delivery
WO2013092998A1 (en) 2011-12-23 2013-06-27 Innate Pharma Enzymatic conjugation of antibodies
HUE043552T2 (hu) 2012-06-08 2019-09-30 Sutro Biopharma Inc Antitestek, amelyek tartalmaznak helyspecifikus nem természetes aminosav maradékokat, eljárások elõállításukra és eljárások használatukra
US9682934B2 (en) 2012-08-31 2017-06-20 Sutro Biopharma, Inc. Modified amino acids
EP3004062B1 (en) 2013-05-24 2017-07-19 SynAffix B.V. Substituted azadibenzocyclooctyne compounds and their use in metal-free click reactions
WO2015006555A2 (en) 2013-07-10 2015-01-15 Sutro Biopharma, Inc. Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
EP2894135A1 (en) 2014-01-10 2015-07-15 Saint-Gobain Placo SAS Method of curing a gypsum calcination product
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
CN104231068A (zh) 2014-01-27 2014-12-24 苏州发士达生物科技有限公司 人白细胞介素ii突变体及其应用
WO2015193897A1 (en) 2014-06-17 2015-12-23 B G Negev Technologies And Applications Ltd At Ben Genetically expanded cell free protein synthesis systems, methods and kits
ES2779977T3 (es) * 2014-07-10 2020-08-21 Univ Zuerich Anticuerpos monoclonales inmunoestimuladores contra interleucina 2 humana
ES2807260T3 (es) 2014-08-11 2021-02-22 Delinia Inc Variantes de IL-2 modificadas que activan selectivamente las células T reguladoras para el tratamiento de enfermedades autoinmunes
HUE055460T2 (hu) * 2014-12-15 2021-11-29 Univ Washington Készítmények és módszerek a célzott citokin bejuttatására
WO2016100889A1 (en) 2014-12-19 2016-06-23 Sutro Biopharma, Inc. Codon optimization for titer and fidelity improvement
US20170369871A1 (en) 2015-01-12 2017-12-28 Synthorx, Inc. Incorporation of unnatural nucleotides and methods thereof
SI3250237T1 (sl) 2015-01-30 2021-11-30 Sutro Biopharma, Inc. Derivati hemiasterlina za konjugacijo in terapijo
WO2017106767A1 (en) 2015-12-18 2017-06-22 The Scripps Research Institute Production of unnatural nucleotides using a crispr/cas9 system
WO2017132617A1 (en) 2016-01-27 2017-08-03 Sutro Biopharma, Inc. Anti-cd74 antibody conjugates, compositions comprising anti-cd74 antibody conjugates and methods of using anti-cd74 antibody conjugates
CN109071679B (zh) * 2016-02-05 2023-07-28 华盛顿大学 用于靶向的细胞因子递送的组合物和方法
US20190216898A1 (en) 2016-05-06 2019-07-18 Wang Mulin Interleukin Combination and Use Thereof
CA3069321A1 (en) 2017-07-11 2019-01-17 The Scripps Research Institute Incorporation of unnatural nucleotides and methods thereof
US20200207859A1 (en) 2017-07-26 2020-07-02 Sutro Biopharma, Inc. Methods of using anti-cd74 antibodies and antibody conjugates in treatment of t-cell lymphoma
KR20250145137A (ko) 2017-08-03 2025-10-13 신톡스, 인크. 자가면역 질환의 치료를 위한 사이토카인 접합체
CA3082117A1 (en) * 2017-11-13 2019-05-16 Bioxcel Therapeutics, Inc. Methods and compositions for treating cancer by modifying multiple arms of the immune system
WO2019113221A1 (en) * 2017-12-06 2019-06-13 The Board Of Trustees Of The Leland Stanford Junior University Engineered proteins to enhance sensitivity of a cell to il-2
IL275426B2 (en) 2017-12-19 2025-03-01 Xencor Inc Engineered il-2 fc fusion proteins
CN111868079B (zh) * 2017-12-27 2025-06-17 协和麒麟株式会社 Il-2变体
KR20200139730A (ko) 2018-03-28 2020-12-14 아센디스 파마 온콜로지 디비전 에이/에스 Il-2 접합체
EP3773681A1 (en) 2018-03-28 2021-02-17 Ascendis Pharma A/S Conjugates
EP3849614B1 (en) 2018-09-11 2023-12-20 Ambrx, Inc. Interleukin-2 polypeptide conjugates and their uses
SG11202107354WA (en) 2019-02-06 2021-08-30 Synthorx Inc Il-2 conjugates and methods of use thereof
US12358986B2 (en) 2019-03-13 2025-07-15 Merck Sharp & Dohme Llc Anti-cancer combination therapies comprising CTLA-4 and PD-1 blocking agents
TWI873169B (zh) 2019-08-15 2025-02-21 美商欣爍克斯公司 使用il-2接合物之免疫腫瘤學組合療法
EP4054644A1 (en) * 2019-11-04 2022-09-14 Synthorx, Inc. Interleukin 10 conjugates and uses thereof
AU2021206449A1 (en) 2020-01-10 2022-07-21 Bright Peak Therapeutics Ag Modified IL-2 polypeptides and uses thereof
MX2023004032A (es) * 2020-10-09 2023-04-27 Synthorx Inc Terapias inmuno-oncologicas con conjugados de il-2.

Also Published As

Publication number Publication date
GEAP202516082A (en) 2025-06-25
PE20231648A1 (es) 2023-10-17
AR121891A1 (es) 2022-07-20
GEP20257834B (en) 2025-12-10
US20240101631A1 (en) 2024-03-28
US20210340207A1 (en) 2021-11-04
US11827684B2 (en) 2023-11-28
IL297329A (en) 2022-12-01
CO2022015044A2 (es) 2022-11-08
CL2022002864A1 (es) 2023-04-21
CA3176515A1 (en) 2021-10-28
EP4139340A1 (en) 2023-03-01
AU2021259426B2 (en) 2024-05-16
JP7415047B2 (ja) 2024-01-16
TW202203973A (zh) 2022-02-01
MX2022013291A (es) 2023-02-14
PH12022552719A1 (en) 2024-02-05
AU2021259426A1 (en) 2022-11-03
WO2021216478A1 (en) 2021-10-28
CR20220530A (es) 2022-12-15
JOP20220266A1 (ar) 2021-10-28
BR112022021482A2 (pt) 2022-12-13
KR20230004682A (ko) 2023-01-06
JP2023515266A (ja) 2023-04-12
CN115916811A (zh) 2023-04-04

Similar Documents

Publication Publication Date Title
ECSP22082943A (es) CONJUGADOS DE INTERLEUCINA 2 HUMANA SESGADOS AL DÍMERO DEL RECEPTOR DE INTERLEUCINA 2 βγc Y CONJUGADOS CON UN POLÍMERO HIDROSOLUBLE NO PEPTÍDICO
CY1125367T1 (el) Δικυκλικοι πεπτιδικοι προσδετες ειδικοι για ερηα2
MX2021002575A (es) Conjugados de polipeptidos de interleucina-2 y sus usos.
CL2023000510A1 (es) Un derivado del dímero de pirrolobenzodiazepina (pbd) reticulado y sus conjugados
CO2022008092A2 (es) N4-hidroxicitidina y derivados y usos antivirales relacionados con los mismos
MX2022003063A (es) Composiciones terapeuticas, combinaciones y metodos de uso.
AR061245A1 (es) Composiciones y metodos para la modulacion del desarrollo vascular
ES2191511B1 (es) Derivados conjugados de eritropoyetina.
CO2024012877A2 (es) Conjugados de fármaco-anticuerpo dirigidos al receptor de folato alfa y métodos de uso
PE20230373A1 (es) Conjugado anticuerpo-farmaco, metodo de preparacion del mismo y uso del mismo
CO2023005889A2 (es) Formulación de conjugado anticuerpo-fármaco de ceacam5
WO2023137156A3 (en) T cell modulatory polypeptides with conjugation sites and methods of use thereof
AU2018268713A1 (en) Biopolymer compositions, scaffolds and devices
WO2021211683A3 (en) Compositions and methods for targeted therapeutic delivery to bone
CL2023000357A1 (es) Agonistas del receptor npy2 solubles
PE20250672A1 (es) Novedoso conjugado de analogo de il-2 inmunoestimulante y procedimiento de preparacion del mismo
ES2103854T3 (es) Peptidos con actividad organo protectiva, procedimiento para la preparacion de los mismos y su utilizacion en la terapia.
CL2025002746A1 (es) Trans-cicloocteno con enlazador-t mejorado
ES2073277T3 (es) Sustancias de naturaleza polipeptida utiles en la terapia humana.
CO2025004806A2 (es) Novedosos anticuerpos anti-napi2b y conjugados-anticuerpo-droga basados en ellos, métodos terapéuticos y usos de los mismos
CL2025002105A1 (es) Proteínas de fusión fc de il-12
CO2025004508A2 (es) Conjugados de anticuerpo-farmaco dirigidos a glipicano-3 y métodos de uso
MX2023006076A (es) Derivados de cannabinoides y su uso en el tratamiento de la inflamación y/o el dolor y/o la obesidad.
AR124463A1 (es) Muteínas de il-2 para el tratamiento de enfermedades autoinmunitarias e inflamatorias
WO2023122587A3 (en) Tripeptide linkers and methods of use thereof